Article Sidebar

PDF (Tiếng Việt)
Published: 2024-07-31
Abstract Views: 107
Views PDF (Tiếng Việt): 78
DOI: https://doi.org/10.52852/tcncyh.v179i6.2487
Issue
Vol. 179 No. 6 (2024)
Section
Các bài báo
How to Cite
Minh, P. N., Hùng, P. M., Quang, N. N., Hoài, N. T. T., Linh, Đinh H., Đạt, P. T., Anh, N. L., & Thăng, L. V. (2024). 16. Clinical and paraclinical characteristics of the first fifteen-cases of percutaneous mitral valve repair in a single center in Vietnam. Journal of Medical Research, 179(6), 144-154. https://doi.org/10.52852/tcncyh.v179i6.2487

16. Clinical and paraclinical characteristics of the first fifteen-cases of percutaneous mitral valve repair in a single center in Vietnam

Pham Nhat Minh, Pham Manh Hung, Nguyen Ngoc Quang, Nguyen Thi Thu Hoai, Dinh Huynh Linh, Phan Tuan Dat, Nguyen Lan Anh, Le Van Thang

Main Article Content

Abstract

Introduction: Percutaneous mitral valve repair intervention to treat mitral valve regurgitation are rapidly increasingly worldwide, but remains limited in Vietnam. The study aims to provide data on the clinical and paraclinical characteristics of the first cases undergoing the Mitraclip procedure in Vietnam. Patients and Methods: This cross - sectional study focused on the first 15 patients undergoing Mitraclip intervention at the Vietnam National Heart Institute, aiming to provide clinical and paraclinical characteristics of this group of this patient cohort. Results: The average age of the patients was 68.0 ± 7.4. All patients presented with symptoms of dyspnea NYHA II and above upon admission. The majority had multiple comorbidities, including hypertension (40.0%), coronary artery disease or history of PCI (26.7%), atrial fibrillation (26.7%), and chronic kidney disease (20.0%). Ultrasonography examination revealed severe mitral valve regurgitation (grade 4+) in all patients, while left ventricular systolic function remained preserved (average LVEF 60.0 ± 13.7% ). Degenerative valve disease was the primary cause of mitral regurgitation (80%). Most patients had an intermediate surgical risk according to the STS classification (mean STS risk score was 3.56 ± 3.9%). Conclusion: This is the first study in Vietnam on the characteristics of patients with mitral regurgitation who underwent Mitraclip procedure.

Article Details

Keywords

Mitral valve regurgitation, percutaneous mitral valve intervention, MitraClip, Vietnam National Heart Institute

References

1. Karagodin I, Singh A, Lang RM. Pathoanatomy of Mitral Regurgitation. Struct Heart. 2020; 4(4): 254-263. doi:10.1080/24748706.2020.1765055.
2. Carpentier AMD, Adams DH, Filsoufi F, Williams M. Carpentier’s reconstructive valve surgery: from valve analysis to valve reconstruction. Saunders/Elsevier; 2010.
3. Accola KD. Commentary: Functional or secondary mitral valve regurgitation: Pathoanatomy versus etiology... changing paradigms and treatment strategies. J Thorac Cardiovasc Surg. Jul 2019; 158(1): 82-83. doi:10.1016/j.jtcvs.2019.03.026.
4. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. Mar 31 2015; 65(12): 1231-1248. doi:10.1016/j.jacc.2015.02.009.
5. De Backer O, Wong I, Taramasso M, Maisano F, Franzen O, Sondergaard L. Transcatheter mitral valve repair: an overview of current and future devices. Open Heart. Apr 2021; 8(1)doi: 10.1136/openhrt-2020-001564.
6. Silva I, Turgeon PY, Paradis JM, et al. Percutaneous Transcatheter Edge-to-Edge Mitral Valve Repair With MitraClip System in the Era of G4. Struct Heart. Mar 2023; 7(2): 100114. doi:10.1016/j.shj.2022.100114.
7. Bushari LI, Reeder GS, Eleid MF, et al. Percutaneous Transcatheter Edge-to-Edge MitraClip Technique: A Practical “Step-by-Step” 3-Dimensional Transesophageal Echocardiography Guide. Mayo Clin Proc. Jan 2019; 94(1): 89-102. doi:10.1016/j.mayocp.2018.10.007.
8. Oliveri F, Al Amri I, Cabezas JM, et al. Mitral valve transcatheter edge-to-edge repair with PASCAL vs MitraClip: A systematic review and meta-analysis. J Invasive Cardiol. Nov 2023; 35(11)doi: 10.25270/jic/23.00218.
9. Matsumoto T, Kubo S, Izumo M, Mizuno S, Shirai S, MitraClip Japan PMSI. MitraClip Treatment of Moderate-to-Severe and Severe Mitral Regurgitation in High Surgical Risk Patients- Real-World 1-Year Outcomes From Japan. Circ J. Oct 29 2021; doi:10.1253/circj.CJ-21-0309.
10. Feldman T, Kar S, Elmariah S, et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol. Dec 29 2015; 66(25): 2844-2854. doi:10.1016/j.jacc.2015.10.018.
11. Mauri L, Garg P, Massaro JM, et al. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J. Jul 2010; 160(1): 23-9. doi:10.1016/j.ahj.2010.04.009.
12. Yeo KK, Yap J, Yamen E, et al. Percutaneous mitral valve repair with the MitraClip: early results from the MitraClip Asia-Pacific Registry (MARS). EuroIntervention. Sep 2014; 10(5): 620-5. doi:10.4244/EIJV10I5A107.
13. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. Dec 13 2018; 379(24): 2307-2318. doi:10.1056/NEJMoa1806640.
14. Okuno T, Izumo M, Shiokawa N, et al. Impact of the MitraClip G4 System on Routine Practice and Outcomes in Patients With Secondary Mitral Regurgitation. Circ J. Mar 25 2024; 88(4): 531-538. doi:10.1253/circj.CJ-23-0503.
15. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. Dec 13 2018; 379(24): 2297-2306. doi:10.1056/NEJMoa1805374.
16. Nishimura RA, Bonow RO. Percutaneous Repair of Secondary Mitral Regurgitation - A Tale of Two Trials. N Engl J Med. Dec 13 2018; 379(24): 2374-2376. doi:10.1056/NEJMe1812279.